CAMBRIDGE, Mass. and EXTON, Pa., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time.
A live audio webcast of Idera's presentation and the question and answer session will be accessible in the Investors and Media section of Idera's website at http://www.iderapharma.com. An archived version will also be available on the Company's website after the event for 90 days.
Also, as a convenience to investors the company will post a copy of the latest corporate slide presentation in the Investors and media section of the Idera website on Monday, January 12, 2015 at 7:00 a.m. Eastern Time.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage patient focused biopharmaceutical company developing novel therapeutic approaches for the treatment of cancer and rare diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics. Idera's immunotherapy approach is based on the modulation of Toll-like receptors (TLRs). In addition to its TLR modulation programs, Idera is developing gene silencing oligonucleotides (GSO) technology that it has created to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
CONTACT: Investor and Media Contact
Robert Doody
Vice President, Investor Relations and
Corporate Communications
484-639-7235
rdoody@iderapharma.com
Idera Pharmaceuticals
